GEN

The Netflix of Digital Biology? Recursion Is Reimagining Drug Discovery

Unmet clinical needs often serve as the fundamental driving force behind drug discovery programs. During lead discovery, an intensive search ensues to find a drug-like small molecule or biological ...
Seeking Alpha

Revisiting Recursion: Big Bets, Big Data, And The Big Cash Burn Rate

Recursion Pharmaceuticals uses high-dimensional data and modern approaches to generate predictive results for drug discovery and development. The company has strengthened its tech stack through ...
Nasdaq

Recursion Announces Two Key Investigational Oncology Drugs Advancing to Clinical Trials, Targeting High Unmet Needs in Hematologic Malignancies, Small-Cell Lung Cancer, & More

REC-3565 is a potential best-in-class MALT1 inhibitor for multiple hematology indications, designed to reduce the risk of hyperbilirubinemia, a common side effect of other MALT1 inhibitors REC-4539, a ...
Nasdaq

Recursion Announces Collaboration and $50 Million Investment from NVIDIA to Accelerate Groundbreaking Foundation Models in AI-Enabled Drug Discovery

SALT LAKE CITY, TORONTO and MONTRÉAL, July 12, 2023 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today ...
GEN

Recursion Eliminating 20% of Workforce, Citing Pipeline Pruning and Capital Markets

Recursion said today it is eliminating approximately 20% of its workforce—about 160 jobs—in a restructuring the AI-based drug developer said reflects both its recently-pruned pipeline and the ...